Cat. No.: HY-10846

Copy Link Print Information

Delamanid

(Synonyms: OPC-67683)

8 Cited Publications

고객리뷰

Based on 8 publication(s) in Google Scholar

Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.95%
CAS No.: 681492-22-8
화학식: C₂₅H₂₅F₃N₄O₆
분자량:534.48

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Delamanid Chemical Structure

CAS No.: 681492-22-8

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (8)
용액&용해도
- In Vitro
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids^[1].

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	CC₅₀	107.5 μg/mL Compound: Delamanid	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 26487912]
MRC5	IC₅₀	>64 μM Compound: 5; OPC-67683	Cytotoxicity against human MRC5 cells assessed as cell viability incubated for 72 hrs by fluorimetric assay Cytotoxicity against human MRC5 cells assessed as cell viability incubated for 72 hrs by fluorimetric assay	[PMID: 26901446]
MRC5	IC₅₀	0.43 μM Compound: 5; OPC-67683	Antitrypanosomal activity against Trypanosoma cruzi infected in human MRC5 cells assessed as parasite growth inhibition incubated for 7 days by chlorophenol red alpha-D-galactopyranoside-based assay Antitrypanosomal activity against Trypanosoma cruzi infected in human MRC5 cells assessed as parasite growth inhibition incubated for 7 days by chlorophenol red alpha-D-galactopyranoside-based assay	[PMID: 26901446]
Vero	CC₅₀	>32 μg/mL Compound: Delamanid	Cytotoxicity against African green monkey vero cells assessed as reduction in cell viability Cytotoxicity against African green monkey vero cells assessed as reduction in cell viability	[PMID: 35777718]

In Vitro

Delamanid inhibits the synthesisi of mucolic acids, cruciala component of the cell wall of the Mycobacterium tuberculosis complex^[1].
Delamanid shows more potent antibacterial activity against drug-susceptible and drug-resistant strains of M. tuberculosis^[2].
Delamanid do not affect rifampin, pyrazinamide, and isoniazid exposure; the ethambutol AUCτ and Cmax values are about 25% higher with delamanid coadministration^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Delamanid (orally administration; 30 mg/kg; 5 days) results in sterile cures in a mouse model of VL^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 681492-22-8
Appearance Solid
분자량 534.48
화학식 C₂₅H₂₅F₃N₄O₆
Color Off-white to yellow
SMILES

FC(F)(F)OC1=CC=C(OC2CCN(C3=CC=C(OC[C@@]4(C)CN5C(O4)=NC([N+]([O-])=O)=C5)C=C3)CC2)C=C1
Synonyms

OPC-67683
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All Microbiological AssayCell Proliferation/Viability AssayELISABio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Colloids Surf B Biointerfaces

Evaluating the biomolecular interaction between delamanid/formulations and human serum albumin by fluorescence, CD spectroscopy and SPR: Effects on protein conformation, kinetic and thermodynamic parameters. [Abstract]

2024 Jul:239:113964. PMID: 38761495
Int J Pharm

Development of a self-microemulsifying drug delivery system to deliver delamanid via a pressurized metered dose inhaler for treatment of multi-drug resistant pulmonary tuberculosis. [Abstract]

2024 Apr 25:655:124031. PMID: 38521375
J Drug Deliv Sci Technol

2024 Oct.
iScience

An assay toolkit for anti-tuberculosis drugs in the hollow fiber system. [Abstract]

2026 Mar 10;29(4):115292. PMID: 41940336
Dis Model Mech

An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor. [Abstract]

2021 Dec 1;14(12):dmm049145. PMID: 34643222

Delamanid purchased from MedChemExpress. Usage Cited in: Dis Model Mech. 2021 Dec 1;14(12):dmm049145. [Abstract]

Delamanid (10 μM) resulted in a significant reduction of the bacterial signal in M. marinum-tdTomato yolk-infected zebrafish embryos.
Tuberculosis

Evaluation of nitroxyl donors' effect on mycobacteria. [Abstract]

2018 Mar:109:35-40. PMID: 29559119
Gene

Unveiling the response of efflux pump genes to delamanid in Mycobacterium tuberculosis H37Rv: a transcriptomic analysis. [Abstract]

2025 Sep 15:965:149661. PMID: 40628310
Drug Dev Ind Pharm

Antimycobacterial and autophagic activity of nebulized delamanid microemulsion targeting alveolar macrophage. [Abstract]

2025 Jul 24:1-16. PMID: 40650441

Delamanid purchased from MedChemExpress. Usage Cited in: Drug Dev Ind Pharm. 2025 Jul 24:1-16. [Abstract]

Effect of pure Delamanid (0-10μg/mL) and selected delamanid-loaded microemulsion formulation on cell viability of a549 (a),ncI-h358 (B) cell line using mtt assay treated with various concentrations after 24 h.

Delamanid purchased from MedChemExpress. Usage Cited in: Drug Dev Ind Pharm. 2025 Jul 24:1-16. [Abstract]

Delamanid (0.125, 0.25, 0.5, 1, 2 μg/mL;24 h) showed no effect in levels of inflammatory cytokines;Il-1β (a), Il-6 (B) produced after expo-sure to nr8383 cells.

Delamanid purchased from MedChemExpress. Usage Cited in: Drug Dev Ind Pharm. 2025 Jul 24:1-16. [Abstract]

Delamanid (0.125, 0.25, 0.5, 1, 2 μg/mL;24 h) showed no effect in lnitric oxide (NO) concentration to nr8383 cells.

Delamanid purchased from MedChemExpress. Usage Cited in: Drug Dev Ind Pharm. 2025 Jul 24:1-16. [Abstract]

The viability was compared among M. bovis samples treated with Delamanid (0.156, 0.313, 0.625, 1.25, 2.5, 5 μg/mL) at varying concentrations.

용액&용해도

In Vitro:

DMSO : 20 mg/mL (37.42 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 2 mg/mL (3.74 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8710 mL

9.3549 mL

18.7098 mL

5 mM

0.3742 mL

1.8710 mL

3.7420 mL

10 mM

0.1871 mL

0.9355 mL

1.8710 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sotgiu G et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther. 2015 Mar;13(3):305-15. [Content Brief]

[2]. Xavier AS et al. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014 Jul;5(3):222-4 [Content Brief]

[3]. Mallikaarjun S et al. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5976-85. [Content Brief]

[4]. Patterson S et al.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. Elife. 2016 May 24;5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	1.8710 mL	9.3549 mL	18.7098 mL	46.7744 mL
DMSO	5 mM	0.3742 mL	1.8710 mL	3.7420 mL	9.3549 mL
	10 mM	0.1871 mL	0.9355 mL	1.8710 mL	4.6774 mL
	15 mM	0.1247 mL	0.6237 mL	1.2473 mL	3.1183 mL
	20 mM	0.0935 mL	0.4677 mL	0.9355 mL	2.3387 mL
	25 mM	0.0748 mL	0.3742 mL	0.7484 mL	1.8710 mL
	30 mM	0.0624 mL	0.3118 mL	0.6237 mL	1.5591 mL

Keywords

Delamanid

8 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Delamanid

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Off-patent Drug Library

Anti-tuberculosis Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Delamanid

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (8)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Delamanid

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Off-patent Drug Library

Anti-tuberculosis Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Delamanid

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (8)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Delamanid Related Classifications

HY-10846 Related Classifications